Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.
Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ. Nafee T, et al. Among authors: harrington ra. Circulation. 2019 Feb 26;139(9):1234-1236. doi: 10.1161/CIRCULATIONAHA.118.038654. Circulation. 2019. PMID: 30802169 No abstract available.
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators.
Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, et al. Tcheng JE, et al. Among authors: harrington ra. Circulation. 1995 Apr 15;91(8):2151-7. doi: 10.1161/01.cir.91.8.2151. Circulation. 1995. PMID: 7697843 Clinical Trial.
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: harrington ra. Circulation. 1999 May 11;99(18):2371-7. doi: 10.1161/01.cir.99.18.2371. Circulation. 1999. PMID: 10318656 Clinical Trial.
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. McClure MW, et al. Among authors: harrington ra. Circulation. 1999 Jun 8;99(22):2892-900. doi: 10.1161/01.cir.99.22.2892. Circulation. 1999. PMID: 10359733 Clinical Trial.
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Harrington RA, et al. Circulation. 2000 Aug 15;102(7):728-35. doi: 10.1161/01.cir.102.7.728. Circulation. 2000. PMID: 10942739 Clinical Trial.
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Roe MT, et al. Among authors: harrington ra. Circulation. 2000 Sep 5;102(10):1101-6. doi: 10.1161/01.cir.102.10.1101. Circulation. 2000. PMID: 10973837
751 results